このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Tibet AIM Pharm マネジメント

マネジメント基準チェック /24

Tibet AIM Pharm'sの CEO はKe Xuで、 Sep2021年に任命され、の在任期間は 3.08年です。は、会社の株式の0.66%を直接所有しており、その価値はCN¥ 11.15M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と3.1年です。

主要情報

Ke Xu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	3.1yrs
CEOの所有権	0.7%
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Jun 07

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

May 02

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Feb 29

CEO（最高経営責任者

Ke Xu (46 yo)

3.1yrs

在職期間

CN¥724,100

報酬

Mr. Ke Xu serves as Chairman of Tibet AIM Pharm. Inc. since February 10, 2023. He serves as General Manager and Director of Tibet AIM Pharm.Inc. since September 13, 2021 and served as its Financial Direct...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ke Xu	GM & Chairman	3.1yrs	CN¥724.10k	0.66% CN¥ 11.1m
Yu Zhang	Deputy GM & Non-Independent Director	3.1yrs	CN¥301.20k	0.20% CN¥ 3.4m
Qianjin Li	Deputy GM & Secretary of the Board of Directors	3.1yrs	CN¥443.90k	0.10% CN¥ 1.7m
Zhou Min	Financial Director & Director	1.7yrs	データなし	データなし

3.1yrs

平均在職期間

45yo

平均年齢

経験豊富な経営陣: 002826の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Ke Xu	GM & Chairman	3.1yrs	CN¥724.10k	0.66% CN¥ 11.1m
Yu Zhang	Deputy GM & Non-Independent Director	3.1yrs	CN¥301.20k	0.20% CN¥ 3.4m
Zhou Min	Financial Director & Director	1.8yrs	データなし	データなし
Zhan Zhou	Vice Chairman	9.8yrs	CN¥301.20k	7.83% CN¥ 131.7m
Ming Hu	Independent Director	3.1yrs	CN¥200.00k	データなし
Xinggang Xiao	Independent Director	3.1yrs	CN¥200.00k	データなし
Lan Feng	Independent Director	3.1yrs	CN¥200.00k	データなし
Ling Li	Chairman of the Supervisory Board	3.1yrs	データなし	0.25% CN¥ 4.1m
Zhongbin Wang	Non-Employee Supervisor	3.1yrs	データなし	データなし

3.1yrs

平均在職期間

46yo

平均年齢

経験豊富なボード: 002826の取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Tibet AIM Pharm マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Recent updates

Tibet AIM Pharm. Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.03 in 2Q 2023)

Tibet AIM Pharm. Inc. to Report First Half, 2024 Results on Aug 16, 2024

Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Tibet Aim Pharm. Inc. Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024

New minor risk - Profit margin trend

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 19%

Tibet AIM Pharm. Inc. to Report Q1, 2024 Results on Apr 26, 2024

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Tibet AIM Pharm. Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Tibet AIM Pharm. Inc. (SZSE:002826) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.066 (vs CN¥0.087 in 3Q 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.019 in 2Q 2022)

Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023

Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in FY 2021)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.042 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.021 in 2Q 2021)

Tibet AIM Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 8 July 2022

Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan

Full year 2021 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in FY 2020)

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.042 (vs CN¥0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.041 in 2Q 2020)

Tibet AIM Pharm. Inc. (SZSE:002826) agreed to acquire 51% stake in Inner Mongolia Bositai Enterprise Management Service Co., Ltd. for CNY 30.6 million.

Tibet AIM Pharm. Inc. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.03 in 1Q 2020)

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2020

New 90-day low: CN¥8.25

New 90-day low: CN¥9.55

New 90-day low: CN¥10.42

New 90-day low: CN¥10.82

Third quarter earnings released

New 90-day low: CN¥11.11

Earnings released

Tibet AIM Pharm. Inc. to Report First Half, 2020 Results on Aug 26, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24